We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Centers for Medicare and Medicaid Services (CMS) issued a proposed rule on Monday that would expand the number of ways Medicare Advantage and Part D plans can negotiate lower drug prices. Read More
The measure would give the federal government the power to ignore patents or market exclusivities and approve cheaper generic versions if branded drugmakers refuse to cut prices as required. Read More
“By approving opioids indicated for the treatment of chronic pain without substantial evidence of their efficacy for this indication, the FDA has helped to facilitate the launch of the U.S. opioid epidemic,” PMRS said. Read More
Generic drugmakers urged the FDA to allow for more flexibility in draft guidance on product identifiers under the Drug Supply Chain Security Act (DSCSA). Read More
Sen. Bernie Sanders (I-Vt.) and Rep. Ro Khanna (D-Calif.) plan to introduce a bill that would limit U.S. prescription drug prices to the median prices in five other nations. Read More
A lawsuit filed in the Southern District of West Virginia alleges marketing tactics by drugmakers and distributors caused children to be born addicted to opioids. Read More
Mallinckrodt’s proposed patient access program for its Acthar gel injection could open the door for fraud and abuse under the Anti-Kickback statute, the HHS Office of the Inspector General (OIG) warned in response to the drugmaker’s inquiries. Read More